MarginsXMarginsX
Home › Markets › Health Care › PVLA

Palvella Therapeutics Inc. (PVLA)

PVLA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$144.60
-5.17% on the day
Market cap
$2.1B
Mid cap
Revenue · 2023
$42.8M
+65.3% on 2022
Net income · 2023
$18.7M
43.7% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2023-12-31, https://www.sec.gov/Archives/edgar/data/1583648/000143774924010123/0001437749-24-010123-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2023-12-31.

Profile

FieldValue
TickerPVLA on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001583648
SEC industry codePharmaceutical Preparations
Incorporated inNV

Financials · 2023

LineValue
Revenue$42.8M
Net income$18.7M
Operating income-$11.9M
Net margin43.7%
Operating margin-27.7%
Revenue growth+65.3%
Cash$7.3M
Total assets$7.5M
P/E (computed)113.1×
P/S (computed)49.4×

Warning signs

Cash runway
53.9 months
$193.3M cash at September 30, 2026
Share count, 1 year
+23.5%
2025-11-01 to 2026-11-02 · +1083.1% over 3 years
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
-$8.9M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$193.3M cash; operating cash flow -$10.8M a quarter.Report 2026-09-30
Shares outstanding14,618,457 (2026-11-02); 11,836,490 a year earlier; 98,851,927 three years earlier. 3y figure adjusted for split (1-for-80 overall).Cover page 2026-11-02
Reverse splits, 3 years1; latest 1-for-80 on 2024-04-23Source 2024-04-23
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2026-02-26
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Philadelphia, Pennsylvania, United StatesPCAOB Form AP 2026-04-10
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $850K, sold $9.7M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$24.6M-$14.4M$193.3MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q2 2026
2026-06-30
Not filed-$21.9M-$12.8M$187.8MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q1 2026
2026-03-31
Not filed-$15.8M-$10.9M$206.4MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q4 2025
2025-12-31
Not filed-$12.7M-$4.9M$58.0M$18.4MNeeds four quarters10-K 2026-03-31
Q3 2025
2025-09-30
Not filed-$11.3M-$7.9M$63.6MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q2 2025
2025-06-30
Not filed-$9.5M-$5.4M$70.4MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q1 2025
2025-03-31
Not filed-$8.2M-$6.8M$75.6MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q4 2024
2024-12-31
Not filed-$4.0M-$5.4M$83.6M$18.4MNeeds four quarters10-K 2026-03-31

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-02-26
Latest annual report10-K2026-03-31
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-11-05
Latest proxyDEFA14A2026-04-30

Source: SEC EDGAR submissions feed, 818 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-13.3%
1 month+18.7%
3 months-2.6%
Year to date+45.7%
1 year+89.4%
From 52-week high-13.3%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
BHVNBiohaven Ltd. Common Shares$13.80-0.14%$2.1B
IMNMImmunome Inc.$17.61-6.18%$2.1B
AUPHAurinia Pharmaceuticals Inc$15.48-1.59%$2.1B
SDGRSchrodinger Inc.$27.36-7.35%$2.1B
PRGOPerrigo Company plc$16.18-0.37%$2.2B
SEPNSepterna Inc.$41.67-2.18%$2.0B
PHVSPharvaris N.V.$32.44-2.76%$2.3B
PBHPrestige Consumer Healthcare Inc.$48.00+3.92%$2.3B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier